Clinical trialPhase 2Completed
Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma
Phase IIa Trial Evaluating the Safety of Intratumoral Injection of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma
- Outcome
- Outcome unknown
- Phase
- Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 1 December 2017
- Expected end
- 15 March 2023
- Enrollment
- 54 participants
- Sites
- 4
- Primary outcomes
- Number of Subjects With Treatment Emergent Adverse Events (Safety and Tolerability)
- Sponsor
- Industry
- Results posted
- 2024-06-24
- Last update
- 24 June 2024
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 3
- Builds on itResponse of Locally Advanced Pancreatic Cancer to Intratumoral Injection of Large Surface Area Microparticle Paclitaxel… DOI 10.1097/mpa.0000000000002236↗
- BackgroundIncreased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. DOI 10.1056/nejmoa1304369↗
- BackgroundNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). DOI 10.1016/j.ejca.2008.10.026↗